Background: The proportion of hyperglycosylated human chorionic gonadotropin (hCG-h) to total human chorionic gonadotropin (%hCG-h) during the first trimester is a promising biomarker for prediction of early-onset pre-eclampsia. We wanted to evaluate the performance of clinical risk factors, mean arterial pressure (MAP), %hCG-h, hCG beta, pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PIGF) and mean pulsatility index of the uterine artery (Uta-PI) in the first trimester in predicting pre-eclampsia (PE) and its subtypes early-onset, late-onset, severe and non-severe PE in a high-risk cohort. Methods: We studied a subcohort of 257 high-risk women in the prospectively collected Prediction and Prevention of Pre-eclamps...
AIM: To determine whether previously identified risk factors are associated with the development of ...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
Background: Early-onset pre-eclampsia with raised blood pressure and protein in the urine before 34 ...
Background: The proportion of hyperglycosylated human chorionic gonadotropin (hCG-h) to total human ...
Abstract Background The proportion of hyperglycosylated human chorionic gonadotropin (hCG-h) to tota...
Background: To study whether maternal serum hyperglycosylated human chorionic gonadotropin (hCG-h) i...
Abstract Background To study whether maternal serum h...
Pre-eclampsia (PE) complicates 2%–8% of all pregnancies and is an important cause of perinatal morbi...
Background: Hypertensive disorders in pregnancy remains a leading cause of maternal morbidity and mo...
Pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. A predic...
Objectives: Maternal serum inhibin-A , pregnancy associated plasma protein-A (PAPP-A) and PAPP-A2 to...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
Objective: Our objective was to determine whether measurement of placenta growth factor (PLGF), inhi...
OBJECTIVES: Abnormal placentation in early pregnancy may play a role in the pathogenesis of pre-ecla...
To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at 11-13 week...
AIM: To determine whether previously identified risk factors are associated with the development of ...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
Background: Early-onset pre-eclampsia with raised blood pressure and protein in the urine before 34 ...
Background: The proportion of hyperglycosylated human chorionic gonadotropin (hCG-h) to total human ...
Abstract Background The proportion of hyperglycosylated human chorionic gonadotropin (hCG-h) to tota...
Background: To study whether maternal serum hyperglycosylated human chorionic gonadotropin (hCG-h) i...
Abstract Background To study whether maternal serum h...
Pre-eclampsia (PE) complicates 2%–8% of all pregnancies and is an important cause of perinatal morbi...
Background: Hypertensive disorders in pregnancy remains a leading cause of maternal morbidity and mo...
Pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. A predic...
Objectives: Maternal serum inhibin-A , pregnancy associated plasma protein-A (PAPP-A) and PAPP-A2 to...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
Objective: Our objective was to determine whether measurement of placenta growth factor (PLGF), inhi...
OBJECTIVES: Abnormal placentation in early pregnancy may play a role in the pathogenesis of pre-ecla...
To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at 11-13 week...
AIM: To determine whether previously identified risk factors are associated with the development of ...
Objective: To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at...
Background: Early-onset pre-eclampsia with raised blood pressure and protein in the urine before 34 ...